drugset / Trial / NCT04400383
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.
Timeline
- Start
- 2020-06-04
- Primary completion
- 2023-07-08
- Completion
- 2023-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AB011 | Monoclonal antibody | 1 mg/kg | — |
| Subject | AB011 | Monoclonal antibody | 10 mg/kg | — |
| Subject | AB011 | Monoclonal antibody | 30 mg/kg | — |
| Subject | AB011 | Monoclonal antibody | 40 mg/kg | — |